Navigation Links
ViroPharma to Present at Three October Healthcare Conferences
Date:10/1/2008

EXTON, Pa., Oct. 1 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the third annual JMP Securities Healthcare Focus Conference at 2:30 P.M. ET on Monday, October 6, 2008. The conference is being held at the Le Parker Meridien Hotel in New York.

ViroPharma also announced that Robert Doody, manager, corporate communications of ViroPharma, will present at the Maxim Group Growth Conference at 10:30 A.M. ET on Tuesday, October 7, 2008. The conference is being held at the Grand Hyatt in New York.

William Roberts, vice president, corporate communications of ViroPharma, will present at the second annual Natixis Bleichroeder Hidden Gems Conference at 8:30 A.M. ET on Monday, October 13, 2008. The conference is being held at the Waldorf=Astoria in New York.

ViroPharma's presentations will be webcast live for investors through http://www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/Products.aspx
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma To Acquire Lev Pharmaceuticals
3. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
4. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
5. ViroPharma to Present at Two Upcoming Healthcare Conferences
6. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
7. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
8. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
9. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
10. ViroPharma to Present at the BIO CEO & Investor Conference
11. ViroPharma Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... -- Research and Markets ( ... "Biotechnology for the Non-Biotechnologist" conference to ... ideal for non-Scientists and Scientists needing to understand ... biotechnology. Ideal for Non-Scientists and Scientists ... and potential of biotechnology Why you ...
(Date:7/6/2015)... , July 6, 2015 ImmunoCellular Therapeutics, Ltd. ... an agreement with Novella Clinical (Novella), to ... patients with newly diagnosed glioblastoma. Novella is a full-service, ... to small to mid-sized oncology companies. The ICT-107 phase ... the US, Europe and ...
(Date:7/3/2015)... , July 3, 2015 ... voivat hakea verkossa osoitteessa  http://www.openinnovationinscience.at ... Open Innovation in Science" -jatkokoulutusohjelmaan ... Boltzmann Gesellschaftin (LBG) tekemän, kansainvälisiä ... mukaan terveystieteiden kaksi suurinta haastetta ...
(Date:7/3/2015)... July 3, 2015 ... september 2015 på  http://www.openinnovationinscience.at till det ... Science" som hålls i Wien ... undersökning med internationella forskare och vetenskapsmän som ... hälsovetenskapens två största utmaningar bristen på incitament ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3
... pediatric emergency personnel across America is undergoing a 21st ... Tech,s College of Engineering, Roanoke-based Carilion Clinic Children,s Hospital, ... 25 years ago. The Broselow Pediatric Emergency Tape ... been a staple of ERs and child trauma units ...
... The Journal of Biological Chemistry announced today that ... Research Institute in La Jolla, Calif., has been ... http://photos.prnewswire.com/prnh/20101206/DC12821 ) Fedor, whose five-year ... journal,s longtime editor, Herbert Tabor, a distinguished researcher ...
... BioSciences Inc. (NYSE Amex: YMI ; TSX: YM) ... enrolled in the Phase I/II trial for its JAK1/JAK2 inhibitor, ... oral presentation at the 52nd American Society of Hematology (ASH) ... is the most serious symptom associated with myelofibrosis, so I ...
Cached Biology Technology:Virginia Tech, Carilion team with physician to create digital ER pediatric response chart 2Virginia Tech, Carilion team with physician to create digital ER pediatric response chart 3Journal of Biological Chemistry names new editor-in-chief 2YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 2YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 3YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 4YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 5YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 6
(Date:6/24/2015)... 24, 2015 The biologics safety testing market ... for the market include growth of the pharmaceutical and ... launches. Over the years, the number of drug approvals ... 2010, the FDA approved 225 drug applications and Health ... Europe accounted for 3,822 of the ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
(Date:6/23/2015)... 2015 Research and ... the "Body-Worn Temperature Sensors Market - Global ... 2014 - 2020" report to their offering. ... the global body-worn temperature sensors market. The global ... the basis of types, care setting, patient demographic, ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... Paleontologists agree that it,s difficult to observe behavior in fossil ... One method is to find a modern, living, species that ... strategy adopted by David L. Meyer, University of Cincinnati professor ... ancient shellfish known as brachiopods. Although they resemble clams or ...
... recent special edition of the journal Fungal Biology Reviews ... Society, features a total of 76 videos which together comprise ... published. The movies were produced by Professor Gero Steinberg of ... in the field of fungal cell biology. The ...
... in Spanish . U.S. Department of ... replacement for methyl bromide are studying an alternative soil treatment ... with USDA,s Agricultural Research Service (ARS) are examining whether a ... be used to replace the popular fumigant. They also are ...
Cached Biology News:Paleontologists audition modern examples of ancient behavior 2Alternatives eyed for methyl bromide 2
Form: Ready to use Applications: Immunohistology-frozen, Immunohistology-paraffin, Western Blot, ELISA...
... Specifications(L x W x H): 17 ... 5/16"18.7 lbsCapacity: 12 slidesTime: Programmable 0 - ... denaturation and hybridization steps 40 user programmable ... and Fixed temperature) Rapid temperature ramp-up from ...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Anti-Mouse Macrophages (Metallophillic), Purified (Clone MOMA-1) (rat IgG2a)...
Biology Products: